Major capsid protein L1 of Human papillomavirus type 16 (HPV16 L1)

The Major capsid protein L1 of Human papillomavirus type 16 (HPV16) is the primary structural component of the HPV16 virion, which is the most prevalent high-risk genotype associated with cervical cancer (UniProt P03101). The L1 protein has the intrinsic ability to self-assemble into virus-like particles (VLPs) that are morphologically identical to the native virus but lack the oncogenic viral DNA, making them ideal antigens for vaccination (NIH National Cancer Institute). These VLPs induce a potent humoral immune response, generating high titers of neutralizing antibodies. These vaccine-induced antibodies specifically target the L1 protein on the surface of the virus, blocking its ability to bind to heparan sulfate proteoglycans on the basement membrane and preventing the infection of basal epithelial cells (PubMed PMID: 16439306). While vaccines like Gardasil and Cervarix are highly effective at preventing new infections, they do not clear pre-existing HPV infections because the L1 protein is typically not expressed in the later stages of the viral life cycle or in HPV-transformed cancerous cells (StatPearls). Consequently, the L1 protein remains the cornerstone of prophylactic strategies against HPV-related malignancies.

Other names

HPV16 L1L1 proteinMajor capsid proteinHuman papillomavirus type 16 L1HPV-16 L1

Induction of neutralizing antibodies that bind to the L1 protein on the viral surface, preventing viral attachment to host cell receptors and subsequent entry into basal epithelial cells.